Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer; and clinical trial collaboration with Neon Therapeutics, Inc. to assess the treatment response to personal cancer vaccine. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-249-9090
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$210.94 million
Profitability
Miscellaneous
Employees893
OptionableOptionable
Natera (NASDAQ:NTRA) Frequently Asked Questions
What is Natera's stock symbol?
Natera trades on the NASDAQ under the ticker symbol "NTRA."
How were Natera's earnings last quarter?
Natera Inc (NASDAQ:NTRA) posted its earnings results on Thursday, November, 8th. The medical research company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.03. The medical research company had revenue of $65.30 million for the quarter, compared to analysts' expectations of $66.42 million. Natera had a negative return on equity of 2,569.52% and a negative net margin of 58.00%. Natera's quarterly revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. View Natera's Earnings History.
When is Natera's next earnings date?
What guidance has Natera issued on next quarter's earnings?
Natera issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $263.2 million.
What price target have analysts set for NTRA?
7 analysts have issued 12 month price targets for Natera's shares. Their predictions range from $20.00 to $41.00. On average, they anticipate Natera's stock price to reach $29.00 in the next year. This suggests a possible upside of 127.6% from the stock's current price. View Analyst Price Targets for Natera.
What is the consensus analysts' recommendation for Natera?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Natera.
Has Natera been receiving favorable news coverage?
News coverage about NTRA stock has been trending negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Natera earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news headlines about the medical research company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the company's share price in the immediate future.
Who are some of Natera's key competitors?
Some companies that are related to Natera include Genomic Health (GHDX), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), Fulgent Genetics (FLGT), PotNetwork (POTN), OpGen (OPGN), First Choice Healthcare Solutions (FCHS), Cancer Genetics (CGIX) and CBA Florida (CBAI).
Who are Natera's key executives?
Natera's management team includes the folowing people:
- Dr. Matthew Rabinowitz, Co-Founder & Exec. Chairman (Age 46)
- Mr. Steve Chapman, CEO (Age 39)
- Mr. Michael Brophy, Chief Financial Officer (Age 39)
- Mr. Jonathan Sheena, Co-Founder, Chief Technology Officer & Director (Age 46)
- Mr. Robert A. Schueren, Chief Operating Officer (Age 57)
When did Natera IPO?
(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
Who are Natera's major shareholders?
Natera's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.86%), Regents of The University of California (0.53%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Natera stock include Claremont Creek Partners Fund, Herm Rosenman, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Institutional Ownership Trends for Natera.
Which institutional investors are selling Natera stock?
NTRA stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Meeder Asset Management Inc. and Peregrine Capital Management LLC. Company insiders that have sold Natera company stock in the last year include Claremont Creek Partners Fund, John Steuart, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy and Steven Leonard Chapman. View Insider Buying and Selling for Natera.
How do I buy shares of Natera?
Shares of NTRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Natera's stock price today?
One share of NTRA stock can currently be purchased for approximately $12.74.
How big of a company is Natera?
Natera has a market capitalization of $787.59 million and generates $210.94 million in revenue each year. The medical research company earns $-136,310,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Natera employs 893 workers across the globe.
What is Natera's official website?
How can I contact Natera?
Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company can be reached via phone at 650-249-9090.
MarketBeat Community Rating for Natera (NASDAQ NTRA)
MarketBeat's community ratings are surveys of what our community members think about Natera and other stocks. Vote "Outperform" if you believe NTRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
